Atty. Dkt. No. 040283/0183

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#21 A

TECHCENTER 1600/2900

Applicant:

Sarkis Barret KALINDJIAN et al.

Title:

Histamine H₃ Receptor Ligands

Appl. No.:

09/622,544

Filing Date:

October 13, 2000

Examiner:

B. Kifle

Art Unit:

1624

AMENDMENT AND REPLY UNDER 37 C.F.R. §1.111

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

This Paper is filed in reply to the *non-final* Office Action mailed on April 23, 2003, for the above-referenced application. This paper is timely filed, *i.e.*, before the end of the shortened statutory period ending on July 23, 2003.

The amendments presented below comply with the revised amendment format permitted by the Notice from the Office of Patent Legal Administration of the U.S. Patent and Trademark Office, dated February 10, 2003. Thus, the provisions of 37 C.F.R. § 1.121(a), (b), (c), and (d) are waived for amendments made to the claims, specification and drawings of this application.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this document.

Remarks/Arguments begin on page 4 of this document.